Results 161 to 170 of about 23,640 (262)

Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE study. [PDF]

ERJ Open Res
Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Caminati M.   +22 more
europepmc   +1 more source

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation.

Int Arch Allergy Immunol
Özden Ş, Tepetam FM, Bozkurt Y, Terzioğlu Şahin F, Aynacı A, Avcı HF, Dursun M, Demirkol MA, Yıldırım N.   +8 more
europepmc   +1 more source

Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2. [PDF]

Clin Exp Allergy
Penz E, Rothe T, Dupont L, Tran TN, Menzies-Gow A, Shavit A, Cohen D, Plate T, Kayaniyil S, Herreman A, Schuoler C, Emmanuel B, Lommatzsch M.   +12 more
europepmc   +1 more source

Asthma and Multimorbidity Amongst Ethnic Minority Groups in High Income Countries

Clinical &Experimental Allergy, EarlyView.
There is a tight intersection between asthma, deprivation, ethnicity, multimorbidity and poor clinical outcomes. An integrated, holistic and culturally tailored approach is needed to improve clinical outcomes amongst ethnic minority groups with asthma and multimorbidity. ABSTRACT Asthma is one of the commonest noncommunicable diseases worldwide.
Mamidipudi Thirumala Krishna, Saibal Moitra, Anna Freeman, Ben Ainsworth, Rebecca Knibb, Ramesh Kurukulaaratchy, Adel H. Mansur   +6 more
wiley   +1 more source

Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment. [PDF]

Int J Mol Sci
Niemiec-Górska A, Labus Ł, Mielcarska S, Glück J, Czuba Z, Cyrnek M, Branicka O, Rymarczyk B, Gawlik R.   +8 more
europepmc   +1 more source

Biomarkers of type 2 inflammation as predictors of response to biologics for severe eosinophilic asthma. [PDF]

ERJ Open Res
Pham DD, Lee JH, Kwon HS, Song WJ, Cho YS, Kim H, Kwon JW, Park SY, Kim S, Hur GY, Kim BK, Nam YH, Yang MS, Kim MY, Kim SH, Lee BJ, Lee T, Park SY, Kim MH, Cho YJ, Park C, Jung JW, Park HK, Kim JH, Moon JY, Bhavsar P, Adcock IM, Chung KF, Kim TB.   +28 more
europepmc   +1 more source

Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis. [PDF]

Pharmaceuticals (Basel)
Maniscalco M, Ambrosino P, Candia C, Di Stefano A, Gnemmi I, Zappa M, Ambrosino N, Visca D, Motta A.   +8 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma. [PDF]

Clin Pharmacokinet
Jin Y, Guiastrennec B, Stuke M, Yao Y, Zhang Y, Barker P, Jison M, Penland RC, Ding J, Lukka PB.   +9 more
europepmc   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source

Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps. [PDF]

Clin Transl Allergy
Mullol J, D'Amato M, de Corso E, Han JK, Tversky J.   +4 more
europepmc   +1 more source